

## PROHIBITION OF SALES TO SWISS RETAIL INVESTORS

These Securities are not intended to be offered, sold, or otherwise made available to and may not be offered, sold or otherwise made available to any retail investor in Switzerland. For these purposes a retail investor means a person who is not a professional or institutional client, as defined in article 4 para. 3, 4 and 5 and article 5 para. 1 and 2 of the Swiss Federal Act on Financial Services of 15 June 2018, as amended ("**FinSA**"). Consequently, no key information document required by FinSA for offering or selling the Securities or otherwise making them available to retail investors in Switzerland has been prepared and therefore, offering or selling the Securities or making them available to retail investors in Switzerland may be unlawful under FinSA.

## PROHIBITION OF OFFERING TO EEA AND UK RETAIL INVESTORS

These Securities are not intended to be offered to and should not be offered to any retail investor in the European Economic Area (EEA) or the United Kingdom (UK). For these purposes, a retail investor means a person who is one (or more) of: (i) a retail client as defined in point (11) of Article 4(1) of Directive 2014/65/EU (as amended, MIFID II); (ii) a customer within the meaning of Directive 2002/92/EC (IMD), where that customer would not qualify as a professional client as defined in point (10) of Article 4(1) of MIFID II; or (iii) not a qualified investor as defined in regulation (EU) 2017/1129 (the "**Prospectus Regulation**").

Final Terms dated: 24.12.2024

# GLOBAL BALANCED AMC

issued by

## CapStone Securities PCC Limited

(a special purpose vehicle incorporated as a protected cell company limited by shares in Guernsey with registered number 74064) (the "**Issuer**")

acting on behalf of Cell GLOBAL BALANCED AMC , a Cell of CapStone Securities PCC Limited

Terms, words and expressions defined in the Base Prospectus shall bear the same meaning in these Final Terms (the "**Final Terms**"). This Security will be issued on the terms of these Final Terms to be read together with the Base Prospectus dated 2 September 2024. These Final Terms shall form an integral part of the Base Prospectus.

The Final Terms do not constitute, and may not be used for the purpose of, an offer or solicitation by anyone in any jurisdiction in which such offer or solicitation is not authorized or to any person to whom it is unlawful to make such offer or solicitation, and no action is being taken to permit an offering of the Securities or the distribution of these Final Terms in any jurisdiction where such action is required.

**These Securities are derivative financial instruments and do not constitute participations in a collective investment scheme within the meaning of the Swiss Federal Act on Collective Investment Schemes, as amended ("CISA"). Therefore, the Securities are not subject to the approval of, or supervision by, the Swiss Financial Markets Supervisory Authority (the "FINMA"). Accordingly, Investors do not have the benefit of the specific investor protection provided under the CISA. Investors bear the issuer risk in relation to the Issuer acting on behalf of its relevant Cell.**

The Products may not be offered or sold unless all applicable laws and regulations in the respective jurisdiction in which an offer, sale, holding and/or delivery of Products is intended or in which the Base Prospectus and these Final Terms are distributed, published and/or held are complied with and if all consents and approvals required in such jurisdiction for the offer, sale, holding and/or delivery of Products have been obtained.

## PART A OF THE FINAL TERMS – CONTRACTUAL TERMS

Terms used herein shall have the meanings given to them in the general terms and conditions (the "**General Terms and Conditions**") set forth in the Base Prospectus dated 2 September 2024 (the "**Base Prospectus**"). The General Terms and the Final Terms together constitute the "**Combined Terms and Conditions**". Full information on CapStone Securities PCC Limited ("**Issuer**"), acting on behalf of the relevant Cell (as defined in Point 9 below) and the offer of the AMCs is only available on the basis of the combination of these Final Terms and the Base Prospectus (and any supplement thereto). The Base Prospectus (together with any supplement thereto) and the Final Terms are available from the Issuer at Suite 6, Provident House, Havilland Street, St. Peter Port, GY1 2QE Guernsey.

### Operational Information

1. Product Type	Actively Managed Certificate
2. SSPA Product Category	Dynamic Tracker-Certificate (Code 1300) of the Swiss Derivative Map, as amended from time to time by the Swiss Structured Products Association (SSPA) (sspa.ch).
3. Valor / ISIN	140662622 / CH1406626221
4. Listing	The Product will not be listed or admitted to trading on an exchange or trading venue.
5. Secondary Market Trading	The Issuer intends to make a market in these Products on a regular basis under normal market conditions. Price indications are available under Bloomberg Corp.
6. Form of Securities	Intermediated Securities ( <i>Bucheffekten</i> ) in accordance with article 973c of the Swiss Code of Obligations.
7. Clearing Systems / Common Depositary	SIX SIS AG, Baslerstrasse 100, P.O. Box, Olten, 4601, Switzerland

### Product Terms and Conditions

8. Issuer	CapStone Securities PCC Limited (a special purpose vehicle incorporated as a protected cell company limited by shares under the laws of Guernsey with registered number 74064)
9. Cell	GLOBAL BALANCED AMC
10. Administrator	Albecq Directors Limited, Suite 6 Provident House, Havilland Street, St Peter Port, GY1 2QE, Guernsey or any successor administrator.
11. Calculation Agent	Banca Credinvest SA, Viale G. Cattori 14, 6902 Lugano, Switzerland or any successor calculation agent.

12. Swap Counterparty	Banca Credinvest SA, Viale G. Cattori 14, 6902 Lugano, Switzerland or any successor swap counterparty.
13. Paying Agent	Banca Credinvest SA, Viale G. Cattori 14, 6902 Lugano, Switzerland or any successor paying agent.
14. Investment Manager	<p>Illumina Capital Management AG, Samstagerstrasse 41, 8832 Wollerau, Switzerland.</p> <p>The Investment Manager is a Swiss portfolio manager and is subject to prudential supervision by FINMA.</p>
15. Investment Strategy	<p>The investment strategy will be a balanced asset allocation with no geographical or sectorial bias and a medium to long term time horizon. The portfolio will be actively managed, and the asset allocation constantly monitored and adjusted based on the evolution of macro-economic scenario. The asset allocation will cover primarily equities and bonds, together with structured products and for the residual part consist of alternative investments (hedge funds, commodities, e.g. gold). The investment strategy will encompass the use of derivatives instruments at discretion of the Strategy-Manager. The portfolio will have currency exposure towards EUR, USD and GBP that might be hedged or not.</p> <p>Please refer to the Appendix for further information on the Investment Guidelines, the Investment Restrictions and the Investment Universe.</p>
16. Hedging Transaction(s)	The Swap Agreements (with limited recourse) between the Issuer and the Swap Counterparty.
17. Underlying Universe	<p>Actively managed basket: the Underlyings may constitute a basket representing a notional actively managed portfolio of assets (the "Constituents") and cash (the "Cash Position").</p> <p>The Underlyings selected and managed by the Investment Manager in accordance with the Investment Strategy.</p>
18. Reinvestment of returns	Any amounts reflecting net dividends and/or interest rates in a real portfolio consisting of the Underlyings will be added to the Cash Position.
19. Initial Weighting of the Underlyings	The Investment Manager starts to implement the Investment Strategy at the first possible trading day after Payment Date (as defined above) according to these Final Terms, the Investment Universe, the Investment Guidelines and the Investment Restrictions. The initial Underlyings will depend on the market conditions at the time the Investment Manager starts to implement the Investment Strategy.
20. Selection / Adjustments / Rebalancing of the Underlyings	The Selection and Adjustments of the composition of the Underlyings are actively made by the Investment Manager by rebalancing the weight or the replacement of the Underlyings at its sole discretion and in compliance with the Investment Strategy, the Investment Guidelines, the Investment Restrictions and the Investment Universe (see Annexes 2 and 3).

The Investment Manager (and neither the Issuer nor the Calculation Agent nor the Swap Custodian, nor the Swap Counterparty, nor the Paying Agent) is solely responsible for ensuring compliance with the Investment Strategy, the Investment Guidelines, and the Investment Restrictions. Neither the Issuer, nor the Paying Agent, nor the Swap Custodian, nor the Swap Counterparty, nor the Calculation Agent, nor any other involved party apart from the Investment Manager carries out any supervision in that regard.

The Issuer may, but is not obliged to, monitor adjustments of the Underlyings which are made at the discretion of the Investment Manager. However, in order to ensure compliance with the Investment Strategy, the Investment Guidelines, and the Investment Restrictions, the Issuer has the right, but is not obliged, to reject Underlyings that form part of a rebalancing.

21. Denomination	One unit
22. Nominal	EUR 92.25
23. Minimum Investment	1 unit
24. Number of Products / Issue Size	25'000 units (with reopening clause)
25. Minimum Trading Lot	One unit
26. Minimum Redemption Amount	The Redemption Amount can be as low as zero (but cannot turn negative).
27. Redemption Amount	<p>The Product units will redeem a cash amount in the Settlement Currency as calculated by the Calculation Agent.</p> <p>The calculation of the Redemption Amount may fluctuate as a result of tracking errors relating to the Underlyings, as described in the Section headed "Risk Factors" set out in the Base Prospectus.</p> <p>The Issuer, acting on behalf of itself or on behalf of its relevant Cell, the Calculation Agent, the Paying Agent, the Swap Custodian and the Swap Counterparty are not liable to Holders of the Product or other third parties for any loss or liability arising from a negative performance of the Investment Strategy.</p>
28. Underlying-Level (t)	The sum of all Underlyings taking into consideration their respective weightings (whereby each Underlying is valued based on the current prices of the Underlying) as calculated by the Calculation Agent on any day t, converted to the

Settlement Currency of the Product at the prevailing exchange rate(s).

The Underlying-Level may not become negative.

29. Prices of the Underlyings	<p>The prices of the Underlyings used as a basis for the calculation of the Underlying-Level are determined at the sole discretion of the Calculation Agent, based either on the values provided by the Swap Custodian, or on the market prices on the exchange of the primary listing of the Underlyings (if listed). Should the specific Underlyings not be listed, then pricing sources like Bloomberg, Reuters, Telekurs etc. might apply.</p> <p>Should one or more of the Underlyings be or become illiquid over the lifetime of the Product, this might implicate a deferred Redemption and/or a modified Redemption Amount, as determined by the Calculation Agent in its sole discretion.</p>
30. Price of the Product (t)	<p>The price of one unit of the Product on a specific day t is equal to the Underlying-Level diminished by all fees, expenses, transaction costs, hedging costs, and taxes (if any) associated with the Investment Strategy and hence divided by the number of outstanding units of the Product on such day t, as calculated by the Calculation Agent.</p>
31. Underlying-Level Calculation Frequency	<p>Weekly, on the last Business Day of the week.</p> <p>In addition, the Issuer may, but is not obliged to, ask the Calculation Agent to calculate the Underlying-Level on any trading day at the Issuer's full discretion</p>
32. Early Redemption Event	<p>The Issuer and the Investment Manager have the right to redeem the Product early at any time without any specific reason, by notifying the Holders of the Product on the earliest possible date.</p>
33. Consequences of an Early Redemption	<p>Following the exercise of a right to redeem the Product early, the Product units will be redeemed at the Redemption Amount as calculated by the Calculation Agent (see above "Redemption Amount")</p> <p>Investors should be aware that the Redemption Amount may be, due to unfavourable market conditions, considerably lower than the Issue Price (as defined above) or the last valuation of the Product before the exercise of the right to redeem the Product early.</p> <p>The Issuer has the right to reduce the Redemption Amount considerably (in certain cases, as low as zero) for important reasons according to the Base Prospectus.</p>
34. Issue Date	23.12.2024

35. Redemption Date	A date specified in the Issuer's Termination Notice, which date shall be no earlier than 10 days after publication of the Termination Notice.										
36. Tenor	Open end.										
37. Settlement Type	Cash settlement.										
38. Settlement Currency	EUR										
39. Management Fee	A Management Fee of 2.00% p.a. (which shall be accrued and deferred on Underlying-Level Calculation Frequency) will be charged to the Product.										
40. Structuring fee, administration fee	<p>A Structuring Fee equal to CHF 6'900 will be charged to the Product on Issue Date.</p> <p>In addition, an Administration Fee, that will be accrued and deferred on Underlying-Level Calculation Frequency, will be applied to the Product in accordance with the following table:</p> <table border="1"> <thead> <tr> <th>Underlying-Level (EUR million)</th><th>Administration Fee</th></tr> </thead> <tbody> <tr> <td>&lt; 2.5</td><td>GBP 2'250 p.a.</td></tr> <tr> <td>2.5 – 5</td><td>GBP 2'850 p.a.</td></tr> <tr> <td>5 – 7.5</td><td>GBP 3'450 p.a.</td></tr> <tr> <td>&gt;7.5</td><td>GBP 4'050 p.a.</td></tr> </tbody> </table>	Underlying-Level (EUR million)	Administration Fee	< 2.5	GBP 2'250 p.a.	2.5 – 5	GBP 2'850 p.a.	5 – 7.5	GBP 3'450 p.a.	>7.5	GBP 4'050 p.a.
Underlying-Level (EUR million)	Administration Fee										
< 2.5	GBP 2'250 p.a.										
2.5 – 5	GBP 2'850 p.a.										
5 – 7.5	GBP 3'450 p.a.										
>7.5	GBP 4'050 p.a.										
41. Performance Fee	<p>A Performance Fee of 15% of the gross outperformance of the High Watermark will be charged to the Product, if the Underlying-Level is above the High Watermark. The High Watermark is calculated net of any fees.</p> <p>At the Issue Date, the High Watermark equals the Issue Price. Thereafter, if the Underlying-Level on an observation date determined in compliance with the Underlying-Level Calculation Frequency is higher than the previous High Watermark, the new High Watermark is set to that level.</p>										
42. Product Life Cycle Management Fee	A Product Life Cycle Management Fee of 0.45% p.a. (minimum CHF 5'000 p.a.) which shall be accrued and deferred on Underlying - Calculation Frequency, will be applied to the Product										

43. Further Fees	A rebalancing / adjustment fee of max. 0.50% of the traded volume is charged to the Underlying-Level for each re-balancing / adjustment made to the Underlyings. Minimum ticket fees may apply.
44. Exchange Rates	Applicable Exchange Rates (if any) for conversion of any amount into the relevant Settlement Currency for the purposes of determining the Underlying-Level or the Redemption Amount, may be sourced from the Swap Custodian (if applicable), or from public sources like Bloomberg (BFIX), Reuters, Telekurs, etc. Relevant is the rate at the time or near the time of the determination of the Underlying-Level or the Redemption Amount.
45. Secondary Market / Market Maker	<p>Secondary market trading will be provided on a best effort basis with a bid offer spread of 0.50% under normal market conditions.</p> <p>On Secondary Market transactions, additional fees (e.g. ticket fees, stamp duty) may apply and are charged to the Underlying-Level.</p>
46. Notices/Adjustments	The Terms and Conditions of this Product may be subject to Adjustments over the lifetime of this Product (e.g. due to Corporate Actions). Notices with respect to Adjustments and all other notices to Investors shall be made as determined in section VI.A.XXV (Notices) of the Base Prospectus.
47. Responsibility	The Issuer accepts responsibility for the information in these Final Terms.
48. Applicable Law / Place of jurisdiction	Swiss law / Zürich, Switzerland
<b>Information regarding the Offer</b>	
49. Offering	No public offer in Switzerland (Private Placement; neither this Document nor the Base Prospectus shall constitute a prospectus pursuant to FinSA)
50. Subscription Period	From the Subscription Start Date (including) to the Subscription End Date (including). The Issuer reserves the right to end the subscription period early or to extend it. The Issuer is not obliged to accept subscription applications. Partial allocations are possible (in particular in the event of oversubscription). The Issuer is not obliged to issue subscribed Products.
51. Subscription Start Date	11.12.2024
52. Subscription End Date	19.12.2024

53. Issue Price	92.25
54. Payment Date	19.12.2024
55. Settlement Date	23.12.2024
56. Business Day	As determined in the General Terms and Conditions of the Base Prospectus.
57. Business Day Convention	Modified following.  USA/US, EEA, Retail Investors in Switzerland, Guernsey.  In and from Switzerland the Product can only be sold to qualified investors as per art. 10 para. 3 and 3ter of the CISA. Furthermore, the product distribution shall comply with any regulatory or contractual selling restrictions that are applicable for the distribution of Products under Swiss law as well as under foreign law.  The Product shall be distributed only by way of private placement; public distribution is not permitted.
58. Selling Restrictions	The Product is not intended to be offered and should not be offered to any retail investor in the European Economic Area ("EEA").  Under no circumstances may the Product be offered or sold to any sanctioned person, entity or country identified by the Office of Foreign Assets Control of the U.S. Department of the Treasury or the U.S. Department of State, the United Nations Security Council, the European Union, Her Majesty's Treasury of the United Kingdom, Swiss sanctions framework implemented by SECO or other relevant sanctions authority.  Please refer to section VI.G.X (Selling Restrictions) of the Base Prospectus for further information.
<b>Tax information</b>	
59. Swiss Withholding Tax	The Product is not subject to the Swiss withholding tax.
60. Swiss stamp duty	The Product may be subject to the Swiss stamp duty of up to 0.3% on the primary as well as the secondary market. There is no Swiss stamp duty upon redemption of the Product. Physical delivery of the underlying securities may be subject to Swiss transfer stamp duty at a rate of up to 0.15% for Swiss securities or up to 0.3% for non-Swiss securities if made by or through the intermediary of a Swiss bank or other securities dealer as defined in the Swiss Stamp Tax Act and no exemption applies



61. Additional Information on Tax Treatment

As set out in the Base Prospectus.

---

**Disclosure of significant Risks for Investors**

---

62. Issuer Risk

Investors in this Product bear the issuer risk. Potential Investors should therefore be aware that they are exposed to the credit risk of the Issuer and its relevant Cell. Hence, Investors bear the risk that the financial situation of the Issuer or its relevant Cell could deteriorate, and the Issuer of the Product may become insolvent.

The Product's value is therefore not only dependent on the performance of the Underlying(s) but also on the creditworthiness of the Issuer, which may change over the term of the Product.

63. Swap Risk

Investors in this Product should be aware that they are exposed to the credit risk of the Swap Custodian and of the Swap Counterparty. Hence, Investors bear the risk that the financial situation of the Swap Custodian and/or of the Swap Custodian could deteriorate, and that the Swap Custodian and/or the Swap Counterparty of the Product may become insolvent.

The Product's value is therefore not only dependent on the performance of the Underlying(s) but also on the creditworthiness of the Swap Custodian and of the Swap Counterparty, which may change over the term of the Product.

The nature of the obligations of the Swap Counterparty to the Issuer under the swap agreements relating to the Product will be limited recourse, meaning that the Swap Counterparty's obligation to pay amounts and the Issuer's entitlement to receive amounts under the Swap Agreements will be strictly limited to amounts actually obtained and received by the Swap Counterparty from the Swap Custodian.

64. Risks compared to a direct Investment in the Underlying(s)

Changes in the value of any underlying or sub-underlying asset may not necessarily lead to a comparable change in the market value of the Securities. As a result, the performance of the Securities may differ significantly from a direct investment in the Underlying(s).

65. Secondary Market

Even though the Issuer intends to make a market in these Products on a regular basis under normal market conditions, the Issuer is under no obligation with respect to Investors to provide any market in this Product at all. Potential Investors should note that there is no guarantee of a specific liquidity or a specific spread (difference between bid and ask prices) or any prices at all. Hence, Potential Investors should not rely on the possibility to buy or sell the Product in a specific point in time or to a specific price. By selling the Product in the secondary market Investors may receive less than the invested capital.

In case of a secondary market transaction, there is a possibility that costs, including taxes, related to or in connection with this Product may arise for Investors that are not paid by the Issuer or imposed by the Issuer.

---

66. Market Disruption

Under certain circumstances set forth in the General Conditions, if the Issuer and/or Calculation Agent determines that a specified Market Disruption Event has occurred, any consequential adjustments in line with Combined Terms and Conditions may have an adverse effect on the value of this Product.

---

67. Volatility

Potential Investors should take into account that market prices for this Product may be volatile, depending upon the development of the price or value of the Underlying(s), interest rates, remaining term of the Product and other factors.

---

68. Risks associated with fees

Parties acting in one or more function(s) (e.g., as issuer, calculation agent, paying agent, investment manager, distributor, broker, market maker, advisor, investment manager, etc.) with respect to Underlying(s) may receive a fee for such function(s), in addition to the fee(s) received for their function(s) at the Securities level. This may lead to potential or actual conflicts of interest.

---

69. Further risks

Considerable risks are associated with investments in the Product, which may not be suitable or appropriate for all investors. Therefore, investors which do not have the knowhow or experience to make their own assessment should seek the advice of trusted advisors in order to understand the suitability and appropriateness of the Product before investing in the Product, and fully understand risks associated to the Product, including, but not limited to:

- the market, credit and liquidity risk with respect to Underlyings, as well as currency risk with respect to Underlyings which are not denominated in the Settlement Currency of the Product (if any);
- the dependency on the continued services of the Investment Manager;
- the risk of sub-optimal adjustments (including, but not limited to, unfavourable timing or signals, insufficient diversification, operational risks, insufficient risk management, adjustments that do not comply with the provisions of the Final Terms) of the Underlyings by the Investment Manager (in particular, due to his high discretion concerning the adjustment of the Underlyings).

Furthermore, Investors are subject to the risk of changes with respect to the regulatory environment or tax considerations that might have an impact on the Product.

With respect to derivatives used as Underlyings (if any), Investors should be aware of the specific risks associated with such derivatives, including, but not limited to, the market risk the price risk, the risk of a margin call, the liquidity risk, the

counterparty risk, and the counterparty risk with respect to the central counterparty.

With respect to currencies (FX) used as Underlyings, they may be subject to risk of inflation, exchange rate risks, and other currency related risks.

In addition, the use of leverage by the Investment Manager may significantly affect the Investment Universe, and in adverse market conditions, generate losses which can erase the entire amount invested.

Markets in some of the investments made as part of Underlyings (e.g. Hedge Funds, Illiquid Notes etc.), if any, may be themselves relatively illiquid, giving rise to potential difficulties in valuing and disposing of such investments, also due to possible soft or hard lock on investors' money, gate or suspend redemptions, wind-down, issue side pockets, or other redemption restrictions.

Even though the Issuer intends to make a market in these Products on a regular basis under normal market conditions, the Issuer is under no obligation with respect to Investors to do so. Investors should note that there is no guarantee of a specific liquidity or a specific spread (difference between bid and ask prices) for the Product. Hence, Investors should not rely on the possibility to buy or sell the Product in a specific point in time or to a specific Price. By selling the Product in the secondary market Investors may receive less than the invested capital.

**ANNEX 1 TO THE FINAL TERMS: UNDERLYINGS (INITIAL COMPOSITION)**

Name	ISIN	Asset class	Currency	Initial Weight %
SIX/SANTANNA AG 23/26	CH1276874117	Structured shares	EUR	6.96
EFG/ESTX,FTSE,ISH,NASDAQ 24/25	CH1322071494	Structured shares	EUR	2.26
EFG/CAC40,FTSEMIB,IBEX35 24/25	CH1373746705	Structured shares	EUR	1.34
LTX/NOVARTIS,ROCHE,NE-STLE	CH1381834204	Structured shares	EUR	1.79
LTX/UBS 24/25	CH1390861941	Structured shares	EUR	0.44
LTX/BAYER N NAMEN 24/26	CH1390864457	Structured shares	EUR	0.14
BNP/ENEL,ENI,BPM,DAV CAM 24/27	XS2576636125	Structured shares	EUR	0.82
CITI/BSKT CGMH 24/26	XS2752793310	Structured shares	EUR	4.62
BNP/NOVARTI,ROCHE,NESTLE 24/26	XS2759161453	Structured shares	EUR	1.02
MAREX GRP/9 ISH CHINA LG 24/27	XS2851755855	Structured shares	EUR	1.83
LTX/PHARUS GLB BOND FUND	CH1265326608	Structured shares	USD	4.49
LTX/GOLD 24/26	CH1336237099	Structured shares	USD	4.64
LTX/STRUCT SOLUTIONS INDEX	CH1194704719	Structured shares	EUR	13.08
EFG/INTL TRACKER PERP 23/49	CH1253171826	Structured shares	EUR	2.6
BNP/NOVARTIS,ROCHE,NE-STLE,UBS	NLBNPLU10QL7	Structured shares	EUR	0.23
ASSET SEGREG/ST GOTTHARD	CH1142529481	Structured shares	USD	1.85
NEXI RG	IT0005366767	Shares	EUR	0.43
ABBOTT LABORATORIES	US0028241000	Shares	USD	0.2
ABBVIE INC	US00287Y1091	Shares	USD	0.2
ALTO INGREDIENTS RG	US0215131063	Shares	USD	1.09
CENCORA INC	US03073E1055	Shares	USD	0.2
ANALOG DEVICES	US0326541051	Shares	USD	0.19
ELEVANCE HEALTH, INC.	US0367521038	Shares	USD	0.2
APPLIED MATERIALS INC	US0382221051	Shares	USD	0.19
GARTNER	US3666511072	Shares	USD	0.22
GENERAL DYNAMICS CORP	US3695501086	Shares	USD	0.23
GILEAD SCIENCES RG	US3755581036	Shares	USD	0.23
HCA HOLDING	US40412C1018	Shares	USD	0.2
IQVIA HOLDINGS RG	US46266C1053	Shares	USD	0.22
KLA RG	US4824801009	Shares	USD	0.23
LOCKHEED MARTIN SHS	US5398301094	Shares	USD	0.22

MCKESSON CORP	US58155Q1031	Shares	USD	0.2
MERCK RG	US58933Y1055	Shares	USD	0.22
MICROCHIP TECHNOLOGY INC SHS	US5950171042	Shares	USD	0.18
MOTOROLA SOLUTIONS INC	US6200763075	Shares	USD	0.21
NIKE INC SHS B	US6541061031	Shares	USD	0.22
ROPER TECHNOLOGIES INC SHS	US7766961061	Shares	USD	0.21
UNITEDHEALTH GROUP INC	US91324P1021	Shares	USD	0.2
VONTOBEL GL ENVIRONMEN- TAL I	LU0384405949	Equitites funds	EUR	1.6
UBAM SICAV 30 GL EQ AC	LU0573559563	Equitites funds	EUR	1.74
SELECTRA INV LAM BIOTECH FD	LU0574994512	Equitites funds	EUR	2.2
VONTO EM M EQ AHIHD	LU0858753618	Equitites funds	EUR	2.35
SELECTRA INV. LAMARCK PHARMA	LU1224032463	Equitites funds	EUR	1.24
PHARUS SICAV BEST REG COMP	LU1868872638	Equitites funds	EUR	1.34
FASANARA TRRE FIN FUND	LU2131880549	Equitites funds	EUR	6.31
PREMIUM AL COM F OP AMC	LU2430038658	Equitites funds	EUR	1.24
VALORI SICAV SUB DE FD AC	LU2460215200	Equitites funds	EUR	2.76
RAMS INV.INDIA EQ PORT.FD II	IE000285C7S2	Equitites funds	USD	2.14
VANEK SEMI USD ETF	IE00BMC38736	Equitites funds	EUR	1.95
BASE INVESTMENTS SICAV BONDS	LU0133519883	Bonds funds	EUR	2.23
PHARUS SICAV LIQ SHS CAP	LU0159791275	Bonds funds	EUR	2.55
VONTOBEL EUR BD	LU0278087860	Bonds funds	EUR	1.48
ZEST ASSET MANAG SICAV QUA EQ	LU0840527526	Bonds funds	EUR	5.38
VONTOBEL EM MKT CORP BD HI	LU1750111533	Bonds funds	EUR	1.47
MONTLAKE UCITS ABR VOL FD	IE000OFMFWU4	Mixed funds	EUR	1.88
HS H/SHARE IDX ETF	HK2828013055	Mixed funds	HKD	0.04
ZEST MEDITERR ABSOLUTE VALUE R	LU1216091931	Alternative funds	EUR	2.12
EFO PRIME ALTERNATIVE FI- NANCE	LU1781276164	Alternative funds	EUR	4.18

## **ANNEX 2 TO THE FINAL TERMS: INVESTMENT GUIDELINES AND INVESTMENT RESTRICTIONS**

It is the sole responsibility of the Investment Manager to ensure that the selection and adjustment of the Underlyings as well as the investments correspond to the Investment Strategy, the Investment Universe, the Investment Guidelines, and the Investment Restrictions. Neither the Issuer, nor the Paying Agent, nor the Swap Counterparty, nor the Swap Custodian, nor the Calculation Agent, nor any other involved party apart from the Investment Manager carries out any supervision in that regard.

### **Investment Guidelines**

The Underlyings are selected, adjusted and rebalanced by the Investment Manager in accordance with the following Investment Guidelines:

1. only assets that comply with the Investment Strategy of the Product (where applicable) may be selected as Underlyings;
2. only Constituents that are included in the Investment Universe may be selected as Underlyings

### **Investment Restrictions**

No restrictions.

## ANNEX 3 TO THE FINAL TERMS: INVESTMENT UNIVERSE

### Investment Universe

The Investment Universe consists of the following asset / asset classes and represents the basis for the selection, adjustment and rebalancing of the Underlyings by the Investment Manager. The Investment Universe may be amended by the Investment Manager at any time and in its sole discretion.

	<b>Asset class</b>	<b>Range allocation (% of total portfolio value)</b>	<b>Permitted instruments</b>
1	Equities	Min 0% - Max 100%	<ul style="list-style-type: none"><li>• Stocks</li><li>• Indices</li><li>• Derivatives</li><li>• Structured Products</li><li>• Funds (including Hedge Funds)</li><li>• ETFs</li></ul>
2	Fixed Income	Min 0% - Max 100%	<ul style="list-style-type: none"><li>• Investment Grade Bonds/Notes</li><li>• High Yield Bonds/Notes</li><li>• Securitisations (ABS, CLOs, CDOs, etc.)</li><li>• Indices</li><li>• Derivatives</li><li>• Structured Products</li><li>• Funds (including Hedge Funds)</li><li>• ETFs</li><li>• Fiduciary deposits</li></ul>
3	Commodities	Min 0% - Max 100%	<ul style="list-style-type: none"><li>• Any commodity (metals, energy resources, agricultural, etc.)</li><li>• Indices</li><li>• Derivatives</li><li>• Structured Products</li><li>• Funds (including Hedge Funds)</li><li>• ETFs</li></ul>
4	FX	Min 0% - Max 100%	<ul style="list-style-type: none"><li>• Any currency (other than the Settlement Currency)</li><li>• Indices</li><li>• Derivatives</li><li>• Structured Products</li><li>• Funds (including Hedge Funds)</li><li>• ETFs</li></ul>
5	Cash	Min 0% - Max 100%	<ul style="list-style-type: none"><li>• Cash in the Settlement Currency</li></ul>